Standard steroid treatment for autoimmune pancreatitis
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Objective: To establish an appropriate steroid treatment regimen for autoimmune pancreatitis (AIP). Methods: A retrospective survey of AIP treatment was conducted in 17 centres in Japan. The main outcome measures were rate of remission and relapse. Results: Of 563 patients with AIP, 459 (82%) received steroid treatment. The remission rate of steroid-treated AIP was 98%, which was significantly higher than that of patients without steroid treatment (74%, 77/104; p<0.001). Steroid treatment was given for obstructive jaundice (60%), abdominal pain (11%), associated extrapancreatic lesions except the biliary duct (11%), and diffuse enlargement of the pancreas (10%). There was no relationship between the period necessary to achieve remission and the initial dose (30 mg/day vs 40 mg/day) of prednisolone. Maintenance steroid treatment was given in 377 (82%) of 459 steroid-treated patients, and steroid treatment was stopped in 104 patients. The relapse rate of patients with AIP on maintenance treatment was 23% (63/273), which was significantly lower than that of patients who stopped maintenance treatment (34%, 35/104; p = 0.048). From the start of steroid treatment, 56% (55/99) relapsed within 1 year and 92% (91/99) relapsed within 3 years. Of the 89 relapsed patients, 83 (93%) received steroid re-treatment, and steroid re-treatment was effective in 97% of them. Conclusions: The major indication for steroid treatment in AIP is the presence of symptoms. An initial prednisolone dose of 0.6 mg/kg/day, is recommend, which is then reduced to a maintenance dose over a period of 3–6 months. Maintenance treatment with low-dose steroid reduces but dose not eliminate relapses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yoshida, K., Toki, F., Takeuchi, T., Watanabe, S.-I., Shiratori, K., & Hayashi, N. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02285209 · Cited by 1,430
Diagnosis of Autoimmune Pancreatitis: The Mayo Clinic Experience
Chari, S. T., Smyrk, T. C., Levy, M. J., Topazian, M. D., Takahashi, N., Zhang, L., Clain, J. E., Pearson, R. K., Petersen, B. T., Vege, S. S., et al. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.05.017 · Cited by 972
Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal
Okazaki, K., Kawa, S., Kamisawa, T., Naruse, S., Tanaka, S., Nishimori, I., Ohara, H., Ito, T., Kiriyama, S., Inui, K., et al. (2006) · Journal of Gastroenterology · doi:10.1007/s00535-006-1868-0 · Cited by 586
Self-citationAutoimmune pancreatitis: proposal of IgG4-related sclerosing disease
Kamisawa, T., & Okamoto, A. (2006) · Journal of Gastroenterology · doi:10.1007/s00535-006-1862-6 · Cited by 466
Self-citationOtsuki, M., Chung, J. B., Okazaki, K., Kim, M.-H., Kamisawa, T., Kawa, S., Park, S. W., Shimosegawa, T., Lee, K., Ito, T., et al. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2205-6 · Cited by 425
Self-citationAutoimmune related pancreatitis: Table 1
Okazaki, K., & Chiba, T. (2002) · Gut · doi:10.1136/gut.51.1.1 · Cited by 417
Self-citationFinkelberg, D. L., Sahani, D., Deshpande, V., & Brugge, W. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra061200 · Cited by 402
Autoimmune Chronic Pancreatitis
Kim, K.-P., Kim, M.-H., Song, M. H., Lee, S. S., Seo, D. W., & Lee, S. K. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30336.x · Cited by 288
Diagnostic criteria for autoimmune chronic pancreatitis revisited
Kim, K.-P. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i16.2487 · Cited by 283
Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment
Hirano, K., Tada, M., Isayama, H., Yagioka, H., Sasaki, T., Kogure, H., Nakai, Y., Sasahira, N., Tsujino, T., Yoshida, H., et al. (2007) · Gut · doi:10.1136/gut.2006.115246 · Cited by 283
Self-citation
Cited by
Stone, J. H., Zen, Y., & Deshpande, V. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1104650 · Cited by 2,616
Kamisawa, T., Zen, Y., Pillai, S., & Stone, J. H. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60720-0 · Cited by 1,212
Self-citationInternational Consensus Guidance Statement on the Management and Treatment of IgG4‐Related Disease
Khosroshahi, A., Wallace, Z. S., Crowe, J. L., Akamizu, T., Azumi, A., Carruthers, M. N., Chari, S. T., Della‐Torre, E., Frulloni, L., Goto, H., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39132 · Cited by 1,064
Self-citationRituximab for IgG4-related disease: a prospective, open-label trial
Carruthers, M. N., Topazian, M. D., Khosroshahi, A., Witzig, T. E., Wallace, Z. S., Hart, P. A., Deshpande, V., Smyrk, T. C., Chari, S., & Stone, J. H. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206605 · Cited by 726
IgG4‐Related Disease: Clinical and Laboratory Features in One Hundred Twenty‐Five Patients
Wallace, Z. S., Deshpande, V., Mattoo, H., Mahajan, V. S., Kulikova, M., Pillai, S., & Stone, J. H. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39205 · Cited by 666
Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis
Hart, P. A., Kamisawa, T., Brugge, W. R., Chung, J. B., Culver, E. L., Czakó, L., Frulloni, L., Go, V. L. W., Gress, T. M., Kim, M.-H., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303617 · Cited by 584
Self-citationPlasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations
Wallace, Z. S., Mattoo, H., Carruthers, M., Mahajan, V. S., Della Torre, E., Lee, H., Kulikova, M., Deshpande, V., Pillai, S., & Stone, J. H. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205233 · Cited by 494
Rituximab for the Treatment of IgG4-Related Disease: Lessons From 10 Consecutive Patients
Khosroshahi, A., Carruthers, M. N., Deshpande, V., Unizony, S., Bloch, D. B., & Stone, J. H. (2012) · Medicine · doi:10.1097/md.0b013e3182431ef6 · Cited by 489
Differences in Clinical Profile and Relapse Rate of Type 1 Versus Type 2 Autoimmune Pancreatitis
Sah, R. P., Chari, S. T., Pannala, R., Sugumar, A., Clain, J. E., Levy, M. J., Pearson, R. K., Smyrk, T. C., Petersen, B. T., Topazian, M. D., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.054 · Cited by 460
IgG4-related disease: an update on pathophysiology and implications for clinical care
Perugino, C. A., & Stone, J. H. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0500-7 · Cited by 421
Hart, P. A., Topazian, M. D., Witzig, T. E., Clain, J. E., Gleeson, F. C., Klebig, R. R., Levy, M. J., Pearson, R. K., Petersen, B. T., Smyrk, T. C., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302886 · Cited by 416
Recent Advances in Autoimmune Pancreatitis
Hart, P. A., Zen, Y., & Chari, S. T. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.010 · Cited by 400
Autoimmune pancreatitis: Imaging features
Dietrich, C., Dong, Y., D'Onofrio, M., Hocke, M., Jenssen, C., Potthoff, A., Atkinson, N., & Ignee, A. (2018) · Endoscopic Ultrasound · doi:10.4103/eus.eus_23_17 · Cited by 380
Mahajan, V. S., Mattoo, H., Deshpande, V., Pillai, S. S., & Stone, J. H. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104708 · Cited by 366
Advances in the diagnosis and management of IgG4 related disease
Lanzillotta, M., Mancuso, G., & Della-Torre, E. (2020) · BMJ · doi:10.1136/bmj.m1067 · Cited by 360
Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis
Sah, R. P., & Chari, S. T. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283413469 · Cited by 340
Histopathologic and Clinical Subtypes of Autoimmune Pancreatitis: The Honolulu Consensus Document
Chari, S. T., Kloeppel, G., Zhang, L., Notohara, K., Lerch, M. M., & Shimosegawa, T. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181e4d9e5 · Cited by 279
Self-citationPathogenic mechanisms of pancreatitis
Manohar, M., Verma, A. K., Venkateshaiah, S. U., Sanders, N. L., & Mishra, A. (2017) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v8.i1.10 · Cited by 269
Huggett, M. T., Culver, E. L., Kumar, M., Hurst, J. M., Rodriguez-Justo, M., Chapman, M. H., Johnson, G. J., Pereira, S. P., Chapman, R. W., Webster, G. J. M., et al. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.223 · Cited by 266
Working members of Research Committee for Intractable Pancreatic Disease and Japan Pancreas Society, Kamisawa, T., Okazaki, K., Kawa, S., Shimosegawa, T., & Tanaka, M. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0221-9 · Cited by 260
Self-citationEuropean Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations
Löhr, J., Beuers, U., Vujasinovic, M., Alvaro, D., Frøkjær, J. B., Buttgereit, F., Capurso, G., Culver, E. L., de‐Madaria, E., Della‐Torre, E., et al. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620934911 · Cited by 252
“A few data on remission rates using low glucocorticoid doses (e.g. equivalent prednisolone dosing of 10–20 mg/day) are available, 14,16 but are too preliminary to be proposed.”
BackgroundInfluentialBuijs, J., van Heerde, M. J., Rauws, E. A. J., de Buy Wenniger, L. J. M., Hansen, B. E., Biermann, K., Verheij, J., Vleggaar, F. P., Brink, M. A., Beuers, U. H. W., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000044 · Cited by 51
Metadata
- Authors
- Kamisawa, T., Shimosegawa, T., Okazaki, K., Nishino, T., Watanabe, H., Kanno, A., Okumura, F., Nishikawa, T., Kobayashi, K., Ichiya, T., Takatori, H., Yamakita, K., Kubota, K., Hamano, H., Okamura, K., Hirano, K., Ito, T., Ko, S. B. H., & Omata, M.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2009-04-26
- Volume
- 58
- Issue
- 11
- Pages
- 1504-1507
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2136489673
- Cited by
- 724
- References
- 21
- FWCI
- 21.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.